Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
45°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Avalyn Pharma Inc.
Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024
May 20, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Announces Multiple Presentations on its Lead Program, AP01, for Pulmonary Fibrosis and its Approach to Developing Novel Inhaled Therapies for Lung Diseases at the 2024 American Thoracic Society International Conference
May 13, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Bolsters Leadership Team with the Appointment of Douglas Carlson as Chief Financial Officer and Chief Business Officer
May 01, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
February 06, 2024
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in the 2023 RBC Capital Markets Healthcare Private Company Conference
December 06, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Presents Data from its AP01 and AP02 Inhaled Therapeutics Programs for Pulmonary Fibrosis
November 09, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
November 06, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Participate in Multiple Upcoming Investor Conferences
October 05, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn to Provide Keynote Presentation at the Formulation & Delivery U.S. 2023 Conference
September 29, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies
September 27, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma’s CEO Leads Workshop on Clinical Strategy at IPF Summit
September 18, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Presents Data Showing Favorable Tolerability and Potential of AP01 to Preserve Forced Vital Capacity in Adults with Pulmonary Fibrosis
September 12, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer
September 11, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma’s Inhaled Pulmonary Fibrosis Programs to be Highlighted at Upcoming ERS International Congress
September 07, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Expands Executive Team with Appointment of Howard M. Lazarus, MD, FCCP to the Role of Chief Medical Officer
August 07, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Invited to Present at Canaccord Genuity Annual Growth Conference
July 27, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Highlighting Inhalation Platform at Upcoming H.C. Wainwright and Hanson Wade Conferences in June
June 15, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Made Corporate and Clinical Presentations at ATS 2023 Including Results of Long-Term Treatment of Pulmonary Fibrosis with AP01
May 23, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Showcasing Therapeutic Approach and Clinical Status at ATS 2023 and the Respiratory Innovation Summit (RIS)
May 11, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Presenting at BioEquity Europe
May 10, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Reports Data After One Year of Treatment in Ongoing AP01 Open-label Extension Trial in Adults with Pulmonary Fibrosis
April 11, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Reports Results of Phase 1 Study of AP02 in Healthy Volunteers and Participants with Idiopathic Pulmonary Fibrosis
March 30, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Publishes Phase 1b ATLAS Results Demonstrating Stabilization of Lung Function at 24 and 48 Weeks with AP01 and Favorable Safety Profile
March 23, 2023
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Invited to Participate in the Annual Evercore ISI HealthCONx Conference
November 28, 2022
From
Avalyn Pharma Inc.
Via
GlobeNewswire
Avalyn Pharma Appoints Lyn Baranowski Chief Executive Officer
October 17, 2022
From
Avalyn Pharma Inc.
Via
Business Wire
Marc Schneebaum Joins Avalyn Pharma as Chief Financial Officer
October 20, 2021
From
Avalyn Pharma Inc.
Via
Business Wire
Avalyn Pharma Reports Statistically Significant Dose Response with Aerosolized Pirfenidone in an Idiopathic Pulmonary Fibrosis Trial
May 24, 2021
From
Avalyn Pharma Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.